Sanofi (SNY)
NASDAQ: SNY · IEX Real-Time Price · USD
48.67
-0.15 (-0.31%)
At close: May 17, 2024, 4:00 PM
48.36
-0.31 (-0.64%)
Pre-market: May 20, 2024, 8:58 AM EDT
Sanofi Revenue
In the year 2023, Sanofi had annual revenue of $51.60B with 6.87% growth.
Revenue (ttm)
$51.60B
Revenue Growth
+6.87%
P/S Ratio
2.16
Revenue / Employee
$599,438
Employees
86,088
Market Cap
111.72B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51.60B | 3.32B | 6.87% |
Dec 31, 2022 | 48.29B | 3.77B | 8.47% |
Dec 31, 2021 | 44.52B | -1.05B | -2.31% |
Dec 31, 2020 | 45.57B | 3.29B | 7.78% |
Dec 31, 2019 | 42.28B | 1.27B | 3.11% |
Dec 31, 2018 | 41.01B | -2.46B | -5.66% |
Dec 31, 2017 | 43.47B | 6.95B | 19.04% |
Dec 31, 2016 | 36.51B | -1.35B | -3.56% |
Dec 31, 2015 | 37.86B | -853.69M | -2.20% |
Dec 31, 2014 | 38.72B | -4.31B | -10.02% |
Dec 31, 2013 | 43.03B | -4.40B | -9.28% |
Dec 31, 2012 | 47.43B | 2.05B | 4.51% |
Dec 31, 2011 | 45.38B | -122.13M | -0.27% |
Dec 31, 2010 | 45.51B | 723.08M | 1.61% |
Dec 31, 2009 | 44.78B | 4.62B | 11.51% |
Dec 31, 2008 | 40.16B | -2.53B | -5.93% |
Dec 31, 2007 | 42.69B | 3.89B | 10.03% |
Dec 31, 2006 | 38.80B | 5.11B | 15.17% |
Dec 31, 2005 | 33.69B | 12.36B | 57.92% |
Dec 31, 2004 | 21.33B | 11.20B | 110.50% |
Dec 31, 2003 | 10.13B | 2.32B | 29.67% |
Dec 31, 2002 | 7.82B | 2.05B | 35.52% |
Dec 31, 2001 | 5.77B | 185.24M | 3.32% |
Dec 31, 2000 | 5.58B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cigna | 206.00B |
Elevance Health | 171.75B |
Bristol-Myers Squibb Company | 45.53B |
GSK | 39.41B |
Medtronic | 32.32B |
Stryker | 20.96B |
Boston Scientific | 14.71B |
Regeneron Pharmaceuticals | 13.10B |
SNY News
- 1 hour ago - Shah Capital ends campaign against Novavax board after Sanofi deal - Reuters
- 6 days ago - Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker - CNBC
- 7 days ago - Sanofi to Spend $1 Billion to Boost Drug Production in France - WSJ
- 7 days ago - Sanofi pledges new 1 bln euros worth of investments in French production sites - Reuters
- 7 days ago - Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty - GlobeNewsWire
- 9 days ago - Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines - Investopedia
- 10 days ago - Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps. - Barrons
- 10 days ago - Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses - Invezz